Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications - PubMed (original) (raw)
. 2005 Apr;446(4):442-50.
doi: 10.1007/s00428-005-1212-8. Epub 2005 Mar 23.
Affiliations
- PMID: 15785925
- DOI: 10.1007/s00428-005-1212-8
Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications
Wilko Weichert et al. Virchows Arch. 2005 Apr.
Abstract
Polo-like kinase (PLK) family members are known to be functionally involved in mitotic signaling and in cytoskeletal reorganization in both normal and malignant cells. In this study, expression of PLK1 and PLK3 was determined immunohistochemically in tissue specimens of 135 breast carcinomas, and expression was correlated with clinicopathological parameters and patient prognosis. Strong PLK isoform overexpression was observed in 42.2% (PLK1) and 47.4% (PLK3) of breast carcinomas when compared with non-transformed breast tissue. A positive correlation of PLK isoform expression with tumor grade, vascular invasion, erbB2/HER-2 expression and markers of proliferative activity was evident. Additionally, an inverse correlation of PLK isoform expression and estrogen receptor status was observed. Overexpression of PLK3 but not of PLK1 was significantly linked to reduced median overall (P<0.001) and relapse-free (P=0.021) survival time. PLK3 expression remained an independent prognostic factor for overall (RR=3.2, P=0.002) and relapse-free (RR=2.9, P=0.049) survival in multivariate survival analysis. These results suggest PLK3 as a novel independent prognostic marker in breast cancer and hint toward a role for PLK isoform overexpression in disease progression. Therefore, in vivo inhibition of PLK family members might represent a rewarding approach in the development of new anticancer drugs for this tumor entity.
Similar articles
- Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Köbel M, Dietel M, Hauptmann S. Weichert W, et al. Br J Cancer. 2004 Feb 23;90(4):815-21. doi: 10.1038/sj.bjc.6601610. Br J Cancer. 2004. PMID: 14970859 Free PMC article. - Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer.
Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, Strebhardt K, Bleyl U. Wolf G, et al. Pathol Res Pract. 2000;196(11):753-9. doi: 10.1016/S0344-0338(00)80107-7. Pathol Res Pract. 2000. PMID: 11186170 - Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.
Singh L, Pushker N, Sen S, Singh MK, Chauhan FA, Kashyap S. Singh L, et al. Clin Exp Ophthalmol. 2015 Aug;43(6):550-7. doi: 10.1111/ceo.12517. Epub 2015 May 13. Clin Exp Ophthalmol. 2015. PMID: 25754767 - Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.
Winkles JA, Alberts GF. Winkles JA, et al. Oncogene. 2005 Jan 10;24(2):260-6. doi: 10.1038/sj.onc.1208219. Oncogene. 2005. PMID: 15640841 Review. - The role of Plk3 in oncogenesis.
Helmke C, Becker S, Strebhardt K. Helmke C, et al. Oncogene. 2016 Jan 14;35(2):135-47. doi: 10.1038/onc.2015.105. Epub 2015 Apr 27. Oncogene. 2016. PMID: 25915845 Review.
Cited by
- High PLK3 levels are linked with less tumor invasion, lower FIGO stage and better prognosis of endometrial cancer.
Zhou W, Wang J, Tian F, Liu P, Li M, Song C, Zhang Y, Yang X, Nie X, Shi Y. Zhou W, et al. Biomark Med. 2024;18(10-12):523-533. doi: 10.1080/17520363.2024.2347192. Epub 2024 May 24. Biomark Med. 2024. PMID: 39082977 - PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells.
Moolmuang B, Chaisaingmongkol J, Singhirunnusorn P, Ruchirawat M. Moolmuang B, et al. Oncol Lett. 2024 May 14;28(1):316. doi: 10.3892/ol.2024.14449. eCollection 2024 Jul. Oncol Lett. 2024. PMID: 38807667 Free PMC article. - Centrosomes and associated proteins in pathogenesis and treatment of breast cancer.
Athwal H, Kochiyanil A, Bhat V, Allan AL, Parsyan A. Athwal H, et al. Front Oncol. 2024 Mar 28;14:1370565. doi: 10.3389/fonc.2024.1370565. eCollection 2024. Front Oncol. 2024. PMID: 38606093 Free PMC article. Review. - PLK1 phosphorylates RhoGDI1 and promotes cancer cell migration and invasion.
Lim J, Hwang YS, Yoon HR, Yoo J, Yoon SR, Jung H, Cho HJ, Lee HG. Lim J, et al. Cancer Cell Int. 2024 Feb 14;24(1):73. doi: 10.1186/s12935-024-03254-z. Cancer Cell Int. 2024. PMID: 38355643 Free PMC article. - Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients.
Shen J, Zhang W, Jin Q, Gong F, Zhang H, Xu H, Li J, Yao H, Jiang X, Yang Y, Hong L, Mei J, Song Y, Zhou S. Shen J, et al. Oncol Res. 2023 Dec 28;32(2):339-351. doi: 10.32604/or.2023.030887. eCollection 2023. Oncol Res. 2023. PMID: 38186570 Free PMC article.
References
- J Cutan Pathol. 2002 Jul;29(6):354-8 - PubMed
- Oncogene. 2002 Sep 9;21(40):6195-200 - PubMed
- Cancer Res. 1999 Jun 15;59(12):2794-7 - PubMed
- Mol Cell. 2002 Mar;9(3):515-25 - PubMed
- Semin Oncol. 2003 Oct;30(5 Suppl 16):38-48 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous